Cargando…

Chromatin accessibility promotes hematopoietic and leukemia stem cell activity

Chromatin organization is a highly orchestrated process that influences gene expression, in part by modulating access of regulatory factors to DNA and nucleosomes. Here, we report that the chromatin accessibility regulator HMGN1, a target of recurrent DNA copy gains in leukemia, controls myeloid dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabal-Hierro, Lucia, van Galen, Peter, Prado, Miguel A., Higby, Kelly J., Togami, Katsuhiro, Mowery, Cody T., Paulo, Joao A., Xie, Yingtian, Cejas, Paloma, Furusawa, Takashi, Bustin, Michael, Long, Henry W., Sykes, David B., Gygi, Steven P., Finley, Daniel, Bernstein, Bradley E., Lane, Andrew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076002/
https://www.ncbi.nlm.nih.gov/pubmed/32179749
http://dx.doi.org/10.1038/s41467-020-15221-z
Descripción
Sumario:Chromatin organization is a highly orchestrated process that influences gene expression, in part by modulating access of regulatory factors to DNA and nucleosomes. Here, we report that the chromatin accessibility regulator HMGN1, a target of recurrent DNA copy gains in leukemia, controls myeloid differentiation. HMGN1 amplification is associated with increased accessibility, expression, and histone H3K27 acetylation of loci important for hematopoietic stem cells (HSCs) and leukemia, such as HoxA cluster genes. In vivo, HMGN1 overexpression is linked to decreased quiescence and increased HSC activity in bone marrow transplantation. HMGN1 overexpression also cooperates with the AML-ETO9a fusion oncoprotein to impair myeloid differentiation and enhance leukemia stem cell (LSC) activity. Inhibition of histone acetyltransferases CBP/p300 relieves the HMGN1-associated differentiation block. These data nominate factors that modulate chromatin accessibility as regulators of HSCs and LSCs, and suggest that targeting HMGN1 or its downstream effects on histone acetylation could be therapeutically active in AML.